Protara Therapeutics Q2 net loss $9.5M; cash $89.6M; pipeline milestones on track

Protara Therapeutics, Inc.

2024-Q2 EPS reported -$1.26

Net loss $9.5M ($0.45/share) vs $11.3M ($1.00/share) in Q2 2023; R&D expenses decreased to $6.4M.
Cash and investments $89.6M at June 30, including $42M net from April private placement; funding expected into 2026.
Expects preliminary data from 6-month evaluable patients in ADVANCED-2 trial (TARA-002 in NMIBC) in Q4 2024.
Pivotal trial dosing for IV Choline Chloride in PN patients expected to begin Q1 2025 after FDA alignment.
Appointed Lisa Schlesinger as VP, Head of New Product Development and Market Access in June 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.